{"schema_version":"secwatch.filing_event.v1","accession":"0000927653-24-000121","form_type":"8-K","ticker":"MCK","cik":"0000927653","company_name":"MCKESSON CORP","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.417922+00:00","generated_at":"2026-05-30T05:02:46.660729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"McKesson Q2 FY2025 revenue $93.7B (+21%), adj. EPS $7.07 (+13%), raises FY25 adj. EPS guidance","bullets":["Revenue $93.7B, +21% YoY; GAAP diluted EPS $1.87 (down 62% vs $4.92); adjusted EPS $7.07 (+13%).","Raises FY2025 adjusted EPS guidance to $32.40-$33.00 from $31.75-$32.55, implying 18-20% growth.","Announced agreement to acquire controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures.","Announced agreement to sell Canada-based Rexall and Well.ca retail businesses."],"urls":{"canonical":"https://secwatch.observer/filing/0000927653-24-000121","json":"https://secwatch.observer/filing/0000927653-24-000121.json","markdown":"https://secwatch.observer/filing/0000927653-24-000121.md","text":"https://secwatch.observer/filing/0000927653-24-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927653/000092765324000121/0000927653-24-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927653/000092765324000121/mck-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:02:46.660729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}